Multispecific Antibody
Development Platform
for Drug Programs
Engineer next-generation bispecific and multispecific antibodies using our proprietary gene-edited mouse platforms. From target identification to IND-ready candidates, we accelerate your preclinical pipeline.
Beyond Monoclonal Antibodies: The Case for Multispecific Drugs
Monoclonal antibodies (mAbs) have transformed oncology and immunology, yet disease complexity often demands more. Multispecific antibodies simultaneously engage two or more molecular targets, enabling mechanisms no conventional mAb can achieve.
-
Synergistic Pathway Dual Inhibition
Block two oncogenic drivers (e.g., HER2 + HER3) with a single molecule, preventing resistance escape routes that arise when only one pathway is suppressed.
-
Immune Cell Redirection (T Cell Engagers)
Bispecific antibody therapy formats such as BiTEs bridge tumor-associated antigens to CD3 on T cells, activating cytotoxic responses in tumors that evade conventional immunotherapy.
-
Improved Tumor Selectivity
Requiring co-expression of two antigens on target cells over healthy tissue reduces off-tumor toxicity, a critical advantage for next-generation multispecific drugs.
-
Simplified Treatment Regimens
Replace combination therapies requiring two separate mAbs with a single multispecific agent, streamlining dosing schedules and reducing patient burden.
Gene-Edited Mouse Platforms for Multispecific Discovery
Our proprietary KY-CLC-mouseTM and KY-HC-mouseTM platforms are purpose-built to solve the hardest challenges in bispecific antibody development: chain pairing fidelity, broad diversity, and nanobody accessibility.
Common Light Chain
Gene-Edited Mouse
The KY-CLC-mouseTM expresses a uniform kappa (κ) light chain modified from a high-frequency murine light chain, while suppressing λ light chain expression. This common κ light chain pairs with diverse heavy chains, eliminating light chain mispairing that plagues conventional bispecific production.
- Identical κ light chain across all antibodies
- No λ light chain expression eliminates mispairing
- Enables facile bispecific antibody assembly
- Diverse heavy chain repertoire preserved
Heavy-Chain Only
Gene-Edited Mouse
The KY-HC-mouseTM produces heavy-chain-only IgGs with broad diversity and high antigen affinity. These homodimeric antibodies lack the conventional light chain, and nanobodies (VHH single-domain antibodies) are derived from them, opening a distinct pathway for next-generation multispecific drugs.
- Heavy-chain-only IgGs with two H-chains
- Nanobody (VHH) derivation for compact formats
- Broad diversity and high antigen affinities
- Excellent tissue penetration for solid tumors
Choose the Right Multispecific Format for Your Mechanism
From IgG-like formats retaining full Fc effector function to compact fragment-based bispecifics with superior tissue penetration, we engineer the architecture best matched to your target biology and clinical goals.
Knob-Into-Hole Bispecific
Engineered CH3 domain mutations guide heterodimeric heavy-chain pairing over homodimers. Combined with common light chains from our CLC platform for clean bispecific production.
BiTE / scFv-Bispecific
Two scFv units joined by a flexible linker with no Fc region. Compact format enables deep tumor penetration and direct T cell engagement.
VHH Bispecific / Trispecific
Derived from KY-HC-mouse heavy-chain-only antibodies, VHH nanobodies are linked to form bispecific and trispecific antibodies.
DVD-IgG / scFv-IgG
Antigen-binding fragments appended N- or C-terminally to a canonical IgG scaffold.
Trispecific Antibody
Three distinct binding arms allow concurrent engagement of tumor antigen, immune effector, and a co-stimulatory receptor.
Bispecific Antibody-Drug Conjugate
A bispecific antibody-drug conjugate merges dual-targeting precision with a cytotoxic payload.
Format Trade-Off Guide
| Format | Fc Effector Function | Serum Half-Life | Tumor Penetration | Immunogenicity Risk | Manufacturability |
|---|---|---|---|---|---|
| Knob-Into-Hole IgG | High | Long (21d) | Limited | Low | Moderate |
| BiTE / scFv Fragment | None | Short (hrs) | Excellent | Moderate | High |
| VHH Nanobody | Optional | Variable | Excellent | Low | High |
| DVD-IgG / scFv-IgG | High | Long (21d) | Limited | Moderate | Moderate |
| Trispecific Antibody | Optional | Variable | Moderate | Moderate | Complex |
| bsADC | High | Long | Limited | Moderate | High Complexity |
Where Multispecifics Stand in the Global Antibody Pipeline
The multispecific antibody field has moved past proof-of-concept. Use these benchmarks to calibrate your program's strategy.
Approved Bispecific Antibody Drugs
Five bispecific antibody drugs have received marketing authorization across hematologic and solid tumor indications.
Clinical Trial Activity
Over 50 bispecific antibodies are being investigated in clinical trials, with cancer immunotherapy representing the plurality.
Trispecific Emerging
Early-phase programs in multiple myeloma and AML showing enhanced response rates over bispecific predecessors.
IO Pipeline Market Share
Represent close to 20% of the clinical antibody pipeline for immuno-oncology and autoimmune disorders.
Anticipating Multispecific Development Challenges
Understanding these trade-offs before committing resources is critical to program success.
Chain Mispairing & Heterodimer Yield
Random heavy and light chain pairing can yield 16+ undesirable combinations. Our KY-CLC-mouse platform solves this at the discovery stage with a common light chain.
Stability, Aggregation & Thermostability
Non-native junctions introduce aggregation-prone regions. AI-guided sequence optimization identifies stable candidates early.
MOA Selection & Indication Fit
Choosing between best-in-class and first-in-class strategies requires thorough target validation and disease biology mapping.
Post-Translational Modification (PTM) Control
Multiple chains increase PTM variability. Robust upstream process development and early analytical characterization catch heterogeneity before IND.
Immunogenicity Management
Humanization, deimmunization, and T-cell assay-based screening at early development stages are embedded in our workflow.
IP Landscape & Freedom to Operate
We map freedom-to-operate early, using novel sequences with favorable biophysical profiles to avoid royalty risk and production bottlenecks.
AI-Assisted Design Accelerates Multispecific Development
Computer-aided antibody design (CAAD) combined with AI enables in silico optimization before experiments begin. We select from 10+ antibody structures, narrow to 3-4 candidates, then apply AI-driven sequence optimization for safety and manufacturability.
Concrete Multispecific MOA Strategies
Multispecific antibodies unlock mechanisms of action impossible with conventional therapeutics.
T Cell Engagement (Tumor x CD3)
Simultaneously bind a tumor-associated antigen and CD3, creating an immunological synapse that activates resting T cells.
Dual Epitope Targeting
Target two non-overlapping epitopes on a single antigen to block all known signaling conformations simultaneously.
Dual Pathway Inhibition
Block two distinct pathways with a single molecule, combating adaptive resistance mechanisms.
Conditional Tissue Targeting
Require co-expression of two antigens to trigger binding, restricting activity to double-positive tumor cells.
NK Cell Engagement
Bridge natural killer cells via CD16 or NKG2D to tumor cells, harnessing innate immune cytotoxicity.
Receptor Crosslinking & Agonism
Force two receptors into proximity to initiate signaling that neither receptor triggers alone.
Advantages of Multispecifics vs. bsADCs
Both offer improved tumor targeting, but differ fundamentally in mechanism, development complexity, and clinical risk profile.
Multispecific antibodies exert effects through immune cell recruitment and pathway modulation. T cell-engaging formats demonstrate durable remissions with manageable toxicity.
A bsADC adds potent cytotoxic payload delivery, enabling activity in antigen-low tumors. However, it introduces significant manufacturing complexity and payload-related toxicity.
The choice depends on tumor biology, antigen expression, immune microenvironment, and manufacturing capabilities.
- No cytotoxic payload required; immune mechanisms are self-amplifying
- Simpler manufacturing: no conjugation chemistry or DAR control needed
- Durable responses via memory T cell and NK cell engagement
- Proven clinical validation: multiple approved agents in hematology
- Favorable half-life when Fc region is retained
- Effective in immunologically cold tumors or T cell-depleted microenvironments
- High CMC complexity: conjugation, DAR distribution, HPAPI handling
- Payload-related hematologic and hepatic toxicity at therapeutic doses
- Narrow therapeutic index requires precise dose optimization
- Synergistic potential when combined with immune checkpoint inhibitors
End-to-End Bispecific Antibody Development Workflow
From target selection to an IND-ready multispecific candidate, our integrated process combines proprietary platform science, AI-aided design, and rigorous CMC development.
Target & MOA Selection
Disease biology mapping, antigen validation, MOA definition
Immunization & Discovery
Gene-edited mouse immunization, antibody screening, hit identification
Bispecific Engineering
Format assembly, AI/CAAD optimization, heterodimer purity maximization
Characterization & CMC
Biophysical profiling, functional assays, process development, stability
IND-Ready Delivery
Regulatory package preparation, preclinical tox support, IND filing readiness
Start Your Multispecific Antibody Development Program
Whether you are selecting a bispecific format, evaluating your first multispecific candidate, or scaling toward IND, our team is ready to partner with your preclinical pipeline.
No commitment required. Typical initial response within 1-2 business days.